As scientists, we often think we understand a virus—its structure, its tricks, the way it moves through the body. But every ...

It's been five years since COVID-19 was declared a global pandemic. As SARS-CoV-2 shifts to endemic status, questions about ...

More information: Shun Nakamura et al, Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes, Proceedings of the National Academy of Sciences (2025).

CoV-2, a new merbecovirus found in bats across China, that utilises the ACE2 receptor for cellular entry—raising concerns ...

A SARS-CoV-2 antibody, NT-108, exhibits potent therapeutic effects in vivo. Cryo-EM structure of the spike complexed with single-chain Fv of NT108 reveals its neutralizing mechanism, providing ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Viruses like SARS-CoV-2 use sugar molecules to hide from the immune system, but scientists at Scripps Research have designed ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations that increased transmissibility or helped the virus evade our immune ...

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep ...